Group 1: Company Overview - Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. is the only domestic enterprise in the neurosurgery field that simultaneously possesses artificial dura (spinal) membrane patches, craniofacial repair and fixation systems, absorbable regenerated oxidized cellulose, and dura mater medical glue [3] - The company has entered the international medical device market since 2011, covering over 100 countries and regions, with nearly 1.3 million products sold [3] Group 2: Financial Performance - In 2024, the domestic operating revenue reached ¥221,750,385.17, accounting for 79.64%, with a year-on-year growth of 22.63% [3] - The overseas operating revenue was ¥56,691,742.22, accounting for 20.36%, with a year-on-year growth of 13.28% [3] - The total revenue growth for 2024 was 20.61%, driven primarily by the artificial dura (spinal) membrane patches, which generated ¥155,593,757.71, accounting for 55.88% of total revenue, with an 11.46% increase [6] Group 3: Product Advantages - The absorbable dura (spinal) membrane patch "Rui Mo®" is the only product in China developed using bio-additive manufacturing technology combined with synthetic materials, offering a unique three-dimensional biomimetic porous micro-fiber structure [5] - The materials used are biodegradable and have good biocompatibility, providing higher biological safety compared to animal-derived materials [6] - The dura (spinal) membrane products generated sales revenue of ¥155,593,757.71, with an 11.46% increase year-on-year [6] Group 4: Future Development Strategy - The company emphasizes value management and aims to enhance core competitiveness while expanding into other surgical fields [4] - Plans to develop hemostatic and medical glue product lines, continuously launching new products to meet clinical needs [7] - The craniofacial repair products achieved sales revenue of ¥79,896,317.05, with a 31.05% increase year-on-year [10]
迈普医学(301033) - 2025年5月15日投资者关系活动记录表